NCT04981145View on ClinicalTrials.gov

The Efficacy and Safety of Iguratimod (IGU) in the Treatment of Primary Sjögren's Syndrome

PHASE4RecruitingINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

January 14, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

July 31, 2025

Conditions
Primary Sjögren's Syndrome
Interventions
DRUG

Iguratimod Tablets

Participants are treated with Iguratimod Tablets 25 mg Twice a day for 24 weeks.

DRUG

Hydroxychloroquine Sulfate Tablets

Participants are treated with Hydroxychloroquine Sulfate Tablets 200 mg Twice a day for 24 weeks.

Trial Locations (1)

310000

RECRUITING

Second affiliated hospital of zhejiang university，school of medical, Hangzhou

All Listed Sponsors
lead

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER